- Home
- CGO vs MNPR Comparison
CGO vs MNPR Comparison
Compare CGO & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGO
- MNPR
- Stock Information
- Founded
- CGO 2004
- MNPR 2014
- Country
- CGO United States
- MNPR United States
- Employees
- CGO N/A
- MNPR N/A
- Industry
- CGO Investment Managers
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- CGO Finance
- MNPR Health Care
- Exchange
- CGO Nasdaq
- MNPR Nasdaq
- Market Cap
- CGO 117.5M
- MNPR 95.5M
- IPO Year
- CGO N/A
- MNPR 2019
- Fundamental
- Price
- CGO $11.73
- MNPR $18.09
- Analyst Decision
- CGO
- MNPR Strong Buy
- Analyst Count
- CGO 0
- MNPR 3
- Target Price
- CGO N/A
- MNPR $27.33
- AVG Volume (30 Days)
- CGO 34.7K
- MNPR 1.5M
- Earning Date
- CGO 01-01-0001
- MNPR 11-08-2024
- Dividend Yield
- CGO 9.25%
- MNPR N/A
- EPS Growth
- CGO N/A
- MNPR N/A
- EPS
- CGO N/A
- MNPR N/A
- Revenue
- CGO N/A
- MNPR N/A
- Revenue This Year
- CGO N/A
- MNPR N/A
- Revenue Next Year
- CGO N/A
- MNPR N/A
- P/E Ratio
- CGO N/A
- MNPR N/A
- Revenue Growth
- CGO N/A
- MNPR N/A
- 52 Week Low
- CGO $7.90
- MNPR $1.37
- 52 Week High
- CGO $10.93
- MNPR $38.50
- Technical
- Relative Strength Index (RSI)
- CGO 44.43
- MNPR 60.19
- Support Level
- CGO $11.49
- MNPR $16.26
- Resistance Level
- CGO $11.84
- MNPR $19.70
- Average True Range (ATR)
- CGO 0.29
- MNPR 2.15
- MACD
- CGO -0.02
- MNPR -0.07
- Stochastic Oscillator
- CGO 36.49
- MNPR 74.36
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in global equities, convertible securities, and high-yield corporate bonds.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.